Neuroendocrine tumors News (3 articles)
|
|
Phase III Novartis data show potential benefit of Afinitor® plus Sandostatin® LAR® in patients with advanced neuroendocrine tumorsEverolimus plus octreotide LAR extended time without tumor growth from 11.3 to 16.4 months versus octreotide LAR alone in advanced NET (carcinoid) patients[1] The study did not reach its primary endpoint of progression-free survival[1] Analyses to adjust for imbalances in... Published on 11 October 2010, 08:28 |
Phase III study shows Novartis drug Afinitor® more than doubles time without tumor growth in advanced pancreatic NET patientsEverolimus extended median progression-free survival from 4.6 to 11.0 months vs. placebo and reduced risk of cancer progression by 65%[1] Patients with advanced pancreatic neuroendocrine tumors (NET) have a rare and aggressive form of cancer with limited treatment options[2,3]... Published on 1 July 2010, 12:15 |
Pivotal Phase III trial of Novartis drug Afinitor® met primary endpoint in study of patients with advanced pancreatic neuroendocrine tumorsRADIANT-3 study results show everolimus significantly extends progression-free survival in patients with advanced pancreatic neuroendocrine tumors (NET) Patients with advanced pancreatic NET have a rare and aggressive form of cancer with limited treatment options[1],[2]... Published on 3 June 2010, 02:50 |
|
Top Categories
We have launched our peer- reviewed, Open-access journal: Insciences Journal
Recently added
27.11.12
Consequential Life Cycle Assessment of Nitrogen Fertilisers Based on Biomass – a Swedish perspective
08.11.12
From Molecular Hollows to Imprinting Strategies – Mass-Sensitive Devices in Host-Guest Chemistry
26.04.12
CdSe/ZnSe Quantum-Dot Semiconductor Optical Amplifiers
23.03.12
Screen-printed Electrochemical Sensors and Biosensors for Monitoring Metal Pollutants